▼ -23.65% Downside Potential
This price target is based on 8 analysts offering 12 month price targets for Personalis in the last 3 months. The average price target is $37.25, with a high forecast of $50.00 and a low forecast of $24.00. The average price target represents a -23.65% upside from the last price of $48.79.
The current consensus among 8 contributing investment analysts is to buy stock in Personalis. This rating has held steady since July 2020, when it changed from a Hold consensus rating.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics. The company also provides a complementary liquid biopsy assay that analyzes various human genes versus. It serves biopharmaceutical customers, universities and non-profits, diagnostics companies, and government entities. Personalis, Inc. has partnership with Berry Genomics. The company was founded in 2011 and is headquartered in Menlo Park, California.